title: Arsenic reverses glioblastoma resistance to mTOR-targeted therapies.
authors.forename: Akio
authors.initials: A
authors.lastname: Iwanami
authors.forename: Timothy F
authors.initials: TF
authors.lastname: Cloughesy
authors.forename: Webster K
authors.initials: WK
authors.lastname: Cavenee
authors.forename: Paul S
authors.initials: PS
authors.lastname: Mischel
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy*; D019008:Drug Resistance, Neoplasm; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000378:metabolism; D000069347:Erlotinib Hydrochloride; D005909:Glioblastoma / Q000188:drug therapy*; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy; D010087:Oxides / Q000627:therapeutic use*; D011799:Quinazolines / Q000627:therapeutic use; D015398:Signal Transduction; D020123:Sirolimus / Q000627:therapeutic use; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D001152:Arsenicals; D010087:Oxides; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; C546842:MTOR protein, human; D066246:ErbB Receptors; D058570:TOR Serine-Threonine Kinases; D000077237:Arsenic Trioxide; D020123:Sirolimus